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The recent rise in penicillin resistance worldwide has led to
the increased use of cephalosporins, macrolides and fluor-
oquinolones as first line therapies in community-acquired
respiratory infections.1 We tested the activity of various
antimicrobial agents against clinical isolates of Streptococ-
cus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis at a tertiary hospital in Lebanon.
A total of 92 isolates (43 S. pneumoniae, 37 H. influenzae
and 12 M. catarrhalis) were recovered from unique conse-
cutive clinical specimens at the American University of Beirut
Medical Center between May 2003 and July 2004. Determina-
tion of the minimal inhibitory concentrations (MICs) of anti-
microbial agents was performed according to the E-test
manufacturer’s protocols (AB Biodisk 2001, E-test Technical
Manual, Solna, Sweden). The following reference bacterial
strains were used: S. pneumoniae (ATCC 49619) and H.
influenzae (ATCC 49247). Results of MICs were interpreted
based on Clinical and Laboratory Standards Institute (CLSI)
breakpoints.2
Most clinical specimens consisted of sputum (33%), naso-
pharynx (18%) and deep tracheal aspirates (16%). S. pneu-
moniae isolates showed uniform susceptibility to
gatifloxacin, levofloxacin and amoxicillin/clavulanate
(Table 1). Susceptibility to penicillin was very low (28%);
intermediate susceptibility and resistance to penicillin was
found in 58% and 14% of isolates, respectively. The six
penicillin-resistant isolates showed uniform resistance to
cefuroxime, azithromycin and clindamycin. S. pneumoniae
isolates recovered from blood (n = 8) exhibited better sus-
ceptibility to penicillin than non-blood isolates (n = 35) (50%
vs. 23%). H. influenzae isolates were highly susceptible
(95—100%) to all tested antimicrobial agents except ampi-
cillin to which eight b-lactamase producing isolates (22%)
were resistant. Twenty-nine H. influenzae isolates (78%)
were serotype b (Mast Diagnostic, Merseyside, UK); the
prevalence of b-lactamase production was similar among
serotype b (21%) and non-serotype b isolates (22%). M.
catarrhalis isolates were uniformly susceptible to all testedantimicrobial agents except ampicillin to which only 5% of
isolates were susceptible. b-Lactamase production was con-
firmed in 95% of isolates.
The latest data from global surveillance studies indicate
that the rates of penicillin resistant S. pneumoniae (PRSP)
vary widely by geographic location.3 Our penicillin resistance
rate of 14% compares well with previous studies from Leba-
non which showed 13% resistance in 1996 and 18% in 1999.4—6
We found that 35% of S. pneumoniae isolates were resis-
tant tomacrolides, amuch higher figure than that reported in
a previous study.4 In addition, all PRSP isolates and a large
proportion of intermediately susceptible isolates were at the
same time resistant to cefuroxime, azithromycin and clin-
damycin. It should be noted that the impact of penicillin
resistance among pneumococcal isolates on clinical outcome
remains unclear. There is evidence to suggest that b-lactams
can still be used to treat non-invasive pneumococcal infec-
tions caused by PRSP if adequate doses are administered.7 On
the other hand, b-lactams should be avoided when treating
PRSP-related meningitis and bloodstream infections.
All tested S. pneumoniae,H. influenzae andM. catarrhalis
isolates were susceptible to levofloxacin and gatifloxacin.
The incidence of fluoroquinolone resistance in the USA and
Europe is low (0—2%).3,8 Higher resistance rates have been
reported from Hong Kong (11%) as a consequence of the
spread of a single resistant clone.3 To date, there have been
no reported cases of resistance to fluoroquinolones among S.
pneumoniae in Lebanon. This is consistent with data from
other countries in the Middle East such as Saudi Arabia and
Qatar.9,10
Gatifloxacin has been shown in clinical trials to be equiva-
lent to b-lactam antibiotics in the treatment of various
respiratory infections.11,12 However, recent reports of dys-
glycemia in patients receiving gatifloxacin and the risk of
selecting for resistance during and following therapy should
be taken into consideration when selecting a therapeutic
agent for respiratory infections.13 For H. influenzae, the
high rates of susceptibility to gatifloxacin can be extrapo-
lated to other new-generation fluoroquinolones such as
moxifloxacin. Although moxifloxacin and gatifloxacin have
the same susceptibility breakpoints, CLSI instructions do not
specify extrapolation for S. pneumoniae isolates. Further
studies should be conducted to confirm moxifloxacin sus-
ceptibility.
Although fluoroquinolone resistance has not yet been
reported in Lebanon, yearly surveillance is recommended,
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Table 1 Susceptibility data for Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
Antimicrobial agent Percent susceptible MIC50 MIC90 MIC range
S. pneumoniae (n = 43)
Penicillin 28 0.38 1.5 0.016—2
Amoxicillin/clavulanate 100 * 0.38 1.5 0.016—2
Cefuroxime 75 0.75 4 0.016—24
Ceftriaxone 93 0.5 1 0.016—4
Azithromycin 65 1 256 0.125—256
Clindamycin 65 0.125 256 0.016—256
Levofloxacin 100 0.5 0.75 0.25—1
Gatifloxacin 100 0.25 0.38 0.125—0.38
H. influenzae (n = 37) *
Ampicillin 78 * 0.125 24 0.047—256
Amoxicillin/clavulanate 95 0.38 1.5 0.19—16
Cefuroxime 95 0.75 1 0.19—12
Ceftriaxone 100 0.016 0.016 0.016—0.38
Azithromycin 95 2 4 0.5—6
Levofloxacin 100 0.012 0.016 0.003—0.032
Gatifloxacin 100 0.012 0.047 0.004—0.38
M. catarrhalis (n = 12)
Ampicillin 5 0.75 1.5 0.032—256
Amoxicillin/clavulanate 100 0.125 0.19 0.016—0.75
Cefuroxime 100 1.5 2 0.38—3
Ceftriaxone 100 0.38 0.75 0.023—0.75
Azithromycin 100 0.125 0.25 0.094—2
Levofloxacin 100 0.032 0.047 0.012—0.047
Gatifloxacin 100 0.032 0.032 0.016—0.47
MIC, minimum inhibitory concentration.
* All the ampicillin-resistant isolates were b-lactamase producers.especially with the increased selective pressure caused by
the widespread use of the fluoroquinolone agents.
Acknowledgements
This work was partially supported by an unrestricted research
fund from Bristol-Myers Squibb.
Conflict of interest: No conflict of interest to declare.
References
1. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, et al.
Macrolide resistance among invasive Streptococcus pneumoniae
isolates. JAMA 2001;286:1857—62.
2. Clinical and Laboratory Standards Institute. Performance stan-
dards for antimicrobial susceptibility testing. Fifteenth infor-
mational supplement M100-S15. Wayne, PA: CLSI; 2005.
3. Felmingham D. Comparative antimicrobial susceptibility of
respiratory tract pathogens. Chemotherapy 2004;50(Suppl 1):
3—10.
4. Araj GF, Bey HA, Itani LY, Kanj SS. Drug-resistant Streptococcus
pneumoniae in the Lebanon: implications for presumptive ther-
apy. Int J Antimicrob Agents 1999;12:349—54.
5. Uwaydah M, Jradeh M, Shihab Z. Antimicrobial resistance of
clinical isolates of Streptococcus pneumoniae in Lebanon. J
Antimicrob Chemother 1996;38:283—6.
6. Uwaydah M, Mokhbat JE, Karam-Sarkis D, Baroud-Nassif R, Roh-
ban T. Penicillin-resistant Streptococcus pneumoniae in Lebanon:
the first nationwide study. Int J Antimicrob Agents 2006;27:
242—6.7. Peterson LR. Penicillins for treatment of pneumococcal pneu-
monia: does in vitro resistance really matter? Clin Infect Dis
2006;42:224—33.
8. Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF,
et al. Cross-resistance, relatedness and allele analysis of fluor-
oquinolone-resistant US clinical isolates of Streptococcus pneu-
moniae (1998—2000). J Antimicrob Chemother 2003;52:
168—75.
9. Elshafie SS, Al-Kuwari J. In vitro activity of moxifloxacin against
community respiratory pathogens in Qatar. Int J Antimicrob
Agents 2004;24:309—10.
10. Memish ZA, Balkhy HH, Shibl AM, Barrozo CP, Gray GC. Strepto-
coccus pneumoniae in Saudi Arabia: antibiotic resistance and
serotypes of recent clinical isolates. Int J Antimicrob Agents
2004;23:32—8.
11. Mandell LA. Safety and efficacy of gatifloxacin in community-
acquired pneumonia: rationale for the Tequin Clinical Experi-
ence Study (TeqCES). Diagn Microbiol Infect Dis 2002;44:
65—7.
12. Nicholson SC, Wilson WR, Naughton BJ, Gothelf S, Webb CD.
Efficacy and safety of gatifloxacin in elderly outpatients with
community-acquired pneumonia. Diagn Microbiol Infect Dis
2002;44:117—25.
13. Frothingham R. Glucose homeostasis abnormalities asso-
ciated with use of gatifloxacin. Clin Infect Dis 2005;41:
1269—76.
Souha S. Kanja,*
Oussayma El-Dbounia
Zeina A. Kanafanib
George F. Arajc
556 Letters to the EditoraDivision of Infectious Diseases,
American University of Beirut Medical Center,
Cairo Street, PO Box 113-6044,
Hamra 110 32090, Beirut, Lebanon
bDivision of Infectious Diseases,
Duke University Medical Center,
Durham, NC, USA
cDepartment of Pathology & Laboratory Medicine,
American University of Beirut Medical Center,
Beirut, Lebanon*Corresponding author.
Tel.: +961 1 350000x5381; fax: +961 1 370814
E-mail address: sk11@aub.edu.lb
(S.S. Kanj)
Corresponding Editor: Timothy Barkham, Singapore
23 August 2006
doi:10.1016/j.ijid.2007.01.012Erythema nodosum associated with Shigella
colitis in a 7-year-old boy
There are only three reported cases of erythema nodosum
being caused by Shigella infections in the literature1 and only
one of these occurred in a pediatric patient.2 We report the
first pediatric case of post-infective erythema nodosum due
to Shigella flexneri in Europe and in the youngest known
patient to date.
A 7-year-old boy was admitted with a five-day history of
vomiting and watery diarrhea. Over the previous few days
fresh blood and mucus was noted in the stool. The frequency
of stool passage was 2—3 stools/hour and was associated with
both perianal and abdominal pain. The rest of the family
remained well and there was no history of recent travel,
uncooked meat, or infectious contacts. The patient was an
immunocompetent child who was growing and developing
normally. There was history of fatigue but no fever.
He was afebrile and well hydrated with normal examina-
tion. Initial sodium was 131 mmol/l, potassium 3.7 mmol/l,
urea 8.0 mmol/l, creatinine 58 mmol/l, and C-reactive pro-
tein 69 mg/l. The total white blood cell count was
5.35  109/l, neutrophil count 3.28  109/l with normal liver
function tests and coagulation. Stool cultures were positive
for Shigella flexneri.
Supportive management with oral rehydration fluid and
analgesia commenced. Six days later, the patient complained
of itchy eyes. However eye and joint examination were
normal and he was discharged home on day six when abdom-
inal pains had ceased.
On day 16, the family raised concerns regarding a rash on
the extensor areas of both upper and lower limbs. Examina-
tion revealed florid erythema nodosum with discrete macu-
lar-papular, erythematous, warm and tender nodules. The
nodules were bilaterally distributed ranging from 1 to 5 cm in
diameter. They lasted a couple of weeks and were treated
symptomatically with non-steroidal anti-inflammatory med-
ication. They did not recur.
Shigella is a global human health problem particularly in
developing countries. In Europe, children in day-care centers
or ofmigrant families aremost at risk.3 Thepredominantmode
of transport is fecal—oral contact and low infectious inoculums
(as few as 10 organisms) makes it highly contagious.4 The
organism generally survives poorly in the environment.S. flexneri is the hyperendemic species in developing
countries and is responsible for approximately 10% of all
diarrheal episodes among young children.3 The species is
highly fragile and may be missed unless care is taken in
collection and handling.
The infection commences with fever, fatigue, malaise, and
anorexia and progresses to watery diarrhea before dysentery.
Persistent diarrhea and malnutrition are the most common
sequelae. A rare post-infectious complication seen mainly in
adults is reactive inflammatory arthritis or in combinationwith
conjunctivitis and urethritis (Reiter’s syndrome).5
Erythema nodosum has an acute onset, characterized by
erythematous, tender, warm nodules, and raised plaques
usually located on the shins, ankles, and knees. Initially
nodules are bright red but within days become livid red
or purplish and finally turn to yellow/green. The list of
etiological factors is varied. Inflammatory bowel disease,
Yersinia enterocolitica, Salmonella typhimurium, and Cam-
pylobacter jejuni gastroenteritis have all been described
in an etiological relationship with the development of
post-infective erythema nodosum. In this case the chron-
ologic correlation between the appearance of S. flexneri
and that of erythema nodosum makes it likely that the two
were etiologically related with no evidence of other pre-
cipitants present. Resolution is spontaneous within a few
weeks and non-steroidal anti-inflammatory medication is
helpful.
Shigella infection in the European pediatric population is
uncommon. The species is fragile and this may explain why
there is limited literature proposing the link between the
infection and erythema nodosum. This case provides further
evidence to support this association.
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